- Home
- NVA vs TNXP Comparison
NVA vs TNXP Comparison
Compare NVA & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVA
- TNXP
- Stock Information
- Founded
- NVA 1987
- TNXP 2007
- Country
- NVA Australia
- TNXP United States
- Employees
- NVA N/A
- TNXP N/A
- Industry
- NVA
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- NVA
- TNXP Health Care
- Exchange
- NVA NYSE
- TNXP Nasdaq
- Market Cap
- NVA 62.5M
- TNXP 71.6M
- IPO Year
- NVA N/A
- TNXP N/A
- Fundamental
- Price
- NVA $11.88
- TNXP $9.17
- Analyst Decision
- NVA
- TNXP Strong Buy
- Analyst Count
- NVA 0
- TNXP 2
- Target Price
- NVA N/A
- TNXP $5,350.00
- AVG Volume (30 Days)
- NVA 31.0K
- TNXP 1.8M
- Earning Date
- NVA 01-01-0001
- TNXP 03-31-2025
- Dividend Yield
- NVA N/A
- TNXP N/A
- EPS Growth
- NVA N/A
- TNXP N/A
- EPS
- NVA N/A
- TNXP N/A
- Revenue
- NVA N/A
- TNXP $11,291,000.00
- Revenue This Year
- NVA N/A
- TNXP $64.71
- Revenue Next Year
- NVA N/A
- TNXP $24.49
- P/E Ratio
- NVA N/A
- TNXP N/A
- Revenue Growth
- NVA N/A
- TNXP 183.05
- 52 Week Low
- NVA $4.35
- TNXP $9.03
- 52 Week High
- NVA $19.00
- TNXP $1,248.00
- Technical
- Relative Strength Index (RSI)
- NVA N/A
- TNXP 33.86
- Support Level
- NVA N/A
- TNXP $11.18
- Resistance Level
- NVA N/A
- TNXP $12.42
- Average True Range (ATR)
- NVA 0.00
- TNXP 2.56
- MACD
- NVA 0.00
- TNXP -0.84
- Stochastic Oscillator
- NVA 0.00
- TNXP 0.82
About NVA NOVA MINERALS LTD SPON ADS EACH REP 60 ORD
Nova Minerals Ltd is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project. It includes projects such as Estelle Gold and Critical Minerals Project, RPM, Korbel, Train and Stoney. It operates in one segment which is exploration of minerals and two geographical areas, being Australia and United States, where Australia derives maximum revenue.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.